🟢 Sellas Life Sciences is trading 4.1% up today, rebounding from dilution fears as the biotech sector rallies

Sellas Life Sciences is trading at $12.98 (up 4.1%) as the stock recovers from a recent selloff triggered by a 20 million-share equity plan expansion and CEO stock award approval.

• Investors are reassessing prior dilution concerns in light of the company's late-stage oncology pipeline and the highly anticipated REGAL Phase 3 trial readout.
• The stock is benefiting from a broader rally in the biotechnology sector driven by strong overall market sentiment.
• The rebound suggests a shift in focus back toward clinical catalysts rather than the immediate impact of the equity plan expansion.